Direct de novo sequencing of therapeutic RNA and impurities via next-generation mass spectrometry

TECHNOLOGY SUMMARY

3D NGMS-Seq is a new tool that reads RNA molecules directly and accurately, even when they're mixed or modified. Unlike older methods, it doesn’t need a reference sequence. It uses advanced mass measurements and smart algorithms to uncover hidden RNA variants, helping improve RNA-based drug development and quality control.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech & Medical

Technology Development Status: Ready to Market

Technology Readiness Level: TRL 9

Vetted Programs/Awards: 1. 1R41HG013624-01 (NHGRI) Title: High-throughput direct sequencing and quantitative mapping of RNA modifications using mass spectrometry Award: $406,500; 09/18/24-08/31/26 2. 1R41HG014125-01 (NHGRI) Title: Exhaustive de novo RNA sequencing of every RNA in a sample by a layer-by-layer mass spectrometry ladder intensity approach Award: $215,088; 09/25/24-08/31/26


SHOWCASE SUMMARY

Organization Type: Startup Technology Company

Website: https://www.directseqbio.com

National Innovation Awardee

MARKET KEYWORDS

Market Keywords: academic/research market, an RNA therapeutics market, and RNA drug compliance